New Kit Enables Rapid PCR on Whole Blood Samples

The Bioline (London, United Kingdom) MyTaq Blood-PCR Kit was specifically engineered to overcome PCR inhibitors typically present in blood samples such as anticoagulants (EDTA, citrate, and heparin) and to give significantly increased sensitivity and success rates even with demanding applications such as GC-rich templates or longer amplicons.

The MyTaq Blood-PCR Kit enables very fast and highly specific direct PCR from a wide range of human and animal whole blood samples. Its novel buffer system eliminates the need for complicated extraction or purification steps or use of additives.

The advanced formulation of the MyTaq Blood-PCR Kit allows fast cycling conditions to be used, without compromising PCR specificity or yield. The addition of an inert red dye in the mix also helps improve throughput. The kit's speed and high specificity make it ideal for multiplex PCR and high-throughput genotyping assays.

Marco Calzavara, president of Bioline, said, "With MyTaq Blood-PCR Kit, researchers can now quickly and easily achieve the purity and yield necessary for high-performance PCR direct from mammalian blood samples. This makes MyTaq Blood-PCR Kit the perfect complement to our widely used PCR reagents.”

Bioline is a wholly owned subsidiary of Meridian Life Science, Inc. (Cincinnati, OH, USA).

Richard L. Eberly, president of Meridian Life Science, Inc., said, "We are delighted to release the MyTaq Blood-PCR Kit which simplifies the process of PCR extractions from whole blood samples. We are committed to our life science customers and to bringing innovation and quality products; such as the MyTaq Blood-PCR Kits to the research laboratory, clinical diagnostic laboratories, and biotechnology companies."

Related Links:
Bioline
Meridian Life Science, Inc.